Astrocyte

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Retrieved on: 
Wednesday, September 14, 2022
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, U.S. Defense Department firefighters, Therapy, United States Army Medical Research and Development Command, Traumatic brain injury, Trial of the century, Safety, Department, MTEC, Policy, Department of Defence, Research, Army, Concussion, Stroke, Government, Patient, Merrell Dow Pharmaceuticals Inc. v. Thompson, Goal, TBI, Brain, Drug discovery, Neurodegeneration, Department of the Army Civilian Police, Pharmaceutical industry, Risk management, Astrocyte

Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, FL.

Key Points: 
  • Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent results during an oral session at the U.S. Defense Department's premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, FL.
  • Our first single-dose Phase 1 clinical study is proceeding as planned, and we have now completed all dose levels in the healthy volunteer subjects.
  • TBI is a top health priority of the military; 22 percent of all combat casualties in recent years are brain injuries, remarked retired Colonel Dallas Hack, M.D., M.P.H., and advisor to Astrocyte.
  • Astrocyte Pharmaceuticals Inc. is a privately held, clinical stage, drug discovery and development company dedicated to accelerating the recovery and well-being of brain injury patients.

CuraSen Therapeutics Announces First Patients Treated with Novel Combination Therapy (CST-2032/CST-107) in Phase 2a Study of Mild Cognitive Impairment (MCI) or Mild Dementia Due to Parkinson’s or Alzheimer’s Disease

Retrieved on: 
Wednesday, September 7, 2022
Professional Services, Health, Neurology, Venture Capital, Clinical Trials, Pharmaceutical, Biotechnology, HIV disease progression rates, Locus coeruleus, Safety, Heart rate, Neuron, LC, Therapy, Arm, Cognition, Doctor of Philosophy, Brain, Microglia, Memory, Even and odd functions, Pericyte, Union, Cell, Neurodegeneration, MCI, Astrocyte, Patient, Arousal, Perfusion, Biomarker, Mutation, Pharmaceutical industry

The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.

Key Points: 
  • The goal of the study is to evaluate the effects of CST-2032 on cognition and mood in patients with mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.
  • The multi-center trial , which is expected to enroll approximately 40 patients, is being conducted in the United States and New Zealand.
  • CuraSen is focused on the development of new treatments for neurodegenerative diseases, including Parkinsons disease, Alzheimers disease and other related orphan conditions.
  • The trials include patients with mild cognitive impairment, Parkinsons disease with rapid eye movement sleep disorder (PDRBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinsons or Alzheimers disease.

VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA

Retrieved on: 
Tuesday, August 23, 2022
Health, Genetics, Other Health, Research, Science, Pharmaceutical, Biotechnology, Amyotrophic lateral sclerosis, Hereditary Disease Foundation, Technology, Research, Neuron, Amsterdam Science Park, Mouse, Poster, CAG, HTT, GMP, Antibody, Astrocyte, Lists of diseases, Therapy, Neurodegeneration, Huntingtin, IPS, AAV, Motor neuron, Vaccine, Vectorial addition chain

Several VecTab candidates were identified that effectively removed huntingtin aggregates from U2OS cells that expressed a CAG-repeat-expanded pathological form of huntingtin.

Key Points: 
  • Several VecTab candidates were identified that effectively removed huntingtin aggregates from U2OS cells that expressed a CAG-repeat-expanded pathological form of huntingtin.
  • Huntingtons Disease is caused by aggregates of polyglutamine-rich HTT protein, which result from CAG repeat expansions of the Huntingtin gene.
  • The poster data shows that the platform is also able to target polyglutamine-rich proteins like HTT, demonstrating the clearance of toxic HTT aggregates.
  • Members of the VectorY team will attend the conference in person and will be available to discuss the poster.

DGAP-News: Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment

Retrieved on: 
Tuesday, August 9, 2022
Death, Emeritus, Tel Aviv Stock Exchange, Survival, Risk, State Security Law in Bahrain, CNS, Financial regulation, Technology, Neuron, Clinical trial, Patent, Brain, Potency (pharmacology), Weizmann Institute of Science, Marketing, Patient, Cell, Company, Projection, Central nervous system, Molecular genetics, Astrocyte, Safety, Neurodegeneration, CSO, KDST, Spinal cord, Diabetes, Israel Prize, Stem cell, TASE, ALS, Paralysis, Disease, Pharmaceutical industry

This US patent joins additional patents granted to Kadimastem in the US, Israel and Europe for the treatment of ALS and for ALS drug screening.

Key Points: 
  • This US patent joins additional patents granted to Kadimastem in the US, Israel and Europe for the treatment of ALS and for ALS drug screening.
  • The cells are intended to support the survival of neurons in the central nervous system (CNS, brain and spinal cord).
  • This situation hampers and annuls the neuromuscular signaling, which negatively affects muscle activity and leads to eventual paralysis and death.
  • The patent announced today strengthens our intellectual property portfolio in the field of ALS and other neurodegenerative diseases.

Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Hallucination, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Chronic pain, NDA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Lists of diseases, Neuron, Annual general meeting, Private Securities Litigation Reform Act, Growth, Brain, Microglia, Schizophrenia, Society, Security (finance), Research, Dopamine, Patient, Therapy, Neurological disorder, Twitter, RPD, Form 10-K, Central nervous system, ACAD, Astrocyte, Safety, Drug development, PIN, Nature, Symptoms of COVID-19, GAAP, Â, Histamine, Delusion, ASCP, Pimavanserin, Nasdaq, Rett syndrome, LinkedIn, Advertising, Annual report, Food, Disease, Pharmaceutical industry, Medical device, Animal, Cryptocurrency, Tutoring

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
  • In the second quarter of 2022, NUPLAZID net sales increased 17% year-over-year, said Steve Davis, Chief Executive Officer.
  • For the six months ended June 30, 2022 and 2021, Acadia reported net product sales of $250.0 million and $221.8 million, respectively.
  • For the six months ended June 30, 2022 and 2021, research and development expenses were $204.5 million and $113.9 million.

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Retrieved on: 
Monday, August 8, 2022
People, U.S. Securities and Exchange Commission, Respiration (physiology), GLOBE, Caudate nucleus, SEC, Cancer, Brain, Behavior, Security (finance), Research, HD, Journal of Neuroinflammation, Diffuse axonal injury, Patient, Tumor microenvironment, Astrocyte, Neurodegeneration, Nature Medicine, Microfilament, Immunosuppression, Health, Disease, Government budget balance, HIV disease progression rates, Inflammation, Neuron, Immunoglobulin G, SEMA4D, Kaufman Assessment Battery for Children, Key finding attacks, Apathy, Nasdaq, Locomotion, Forward-looking statement, Microglia, SIGNAL, Caregiver, Neoplasm, Cell, COVID-19, Program, Mutation, Dementia, Atrophy, Cognition, B cell, FDG-PET, Company, Problem solving, Pharmaceutical industry, Medical imaging, Vaccine, Risk management, Journal

ROCHESTER, N.Y., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced that results of its Phase 2 SIGNAL study to evaluate its SEMA4D-blocking antibody, pepinemab, in patients with Huntington’s Disease (HD) were published in the August 8, 2022 issue of Nature Medicine1, a leading journal for publication of translational and clinical research. In parallel, a second report has been published in the Journal of Neuroinflammation2 detailing the pathologic impact of SEMA4D on neuroinflammatory cells in both HD and Alzheimer’s disease (AD).

Key Points: 
  • These findings encourage continued development of pepinemab as a potential therapy for patients with early manifest symptoms of HD and potentially AD.
  • Accordingly, a phase 1b/2a study of pepinemab in Alzheimers disease has been initiated and is actively enrolling patients (NCT04381468).
  • The mechanism of action of pepinemab, targeting neuroinflammation2, may provide an alternative to other AD therapies that target aggregates of A amyloid.
  • The Nature Medicine publication is available online at https://www.nature.com/articles/s41591-022-01919-8 and Journal of Neuroinflammation at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-022... ; both articles will also be posted on the Vaccinex website.

Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022

Retrieved on: 
Tuesday, August 2, 2022
CA, Neuron, AAIC, Government budget balance, Precision medicine, McGill University, Dementia, GLOBE, Rett syndrome, McGill, Learning, Social, Twitter, Instagram, Research, Doctor of Philosophy, The Michael J. Fox Foundation, Microglia, SEC, FTD, Drug discovery, Morris water navigation task, CNS, Adult, Nature, Cancer, Conference, Lists of diseases, Frontotemporal dementia, Degenerative disease, Central nervous system, Epilepsy, SIGMAR1, FDA, Biomarker, Patient, LinkedIn, Pain, Therapy, Amyloid, Annual report, Astrocyte, Hippocampus, Mouse, RATS, Central nervous system disease, Pharmaceutical industry, Trapping, Facebook

Subsequently, after one month of drug interruption, behavioral tests were performed: Novel Object Recognition, Morris Water Maze, and Social Preference.

Key Points: 
  • Subsequently, after one month of drug interruption, behavioral tests were performed: Novel Object Recognition, Morris Water Maze, and Social Preference.
  • Biomarker analysis revealed that ANAVEX3-71 prevents McGill-APP transgenic rats from increasing cortical (p 0.05) and hippocampal (p 0.01) extracellular A deposition.
  • ANAVEX3-71 also significantly reduces microglia (p 0.05) and astrocytes (p 0.05) recruitment towards A-burdened neurons in the hippocampus.
  • In the Novel Object Recognition behavioral test, Tg control rats explored the novel object significantly less than wt control rats (p 0.01).

Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer’s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer’s Disease

Retrieved on: 
Friday, July 29, 2022
Cloud, Association, Neuron, Brain, Neoplasm, Dementia, GLOBE, U.S. Securities and Exchange Commission, Neurodegeneration, Microglia, Forward-looking statement, SEC, Research, Science by press conference, Muscle atrophy, COVID-19, Safety, Conference, Cancer, Inflammation, AD, Security (finance), SEMA4D, SIGNAL, Patient, Nasdaq, Astrocyte, Cognition, Immunoglobulin G, HD, Pharmaceutical industry, Vaccine, Medical imaging

Additional information about the study is available at: https://www.vaccinex.com/patient-signal-ad-trial/

Key Points: 
  • Additional information about the study is available at: https://www.vaccinex.com/patient-signal-ad-trial/
    SEMA4D is upregulated in neurons during progression of Alzheimers (AD) and Huntingtons Disease (HD).
  • The ongoing SIGNAL-AD study is evaluating the safety, tolerability and the effects on cognition and brain metabolic activity of pepinemab in early AD.
  • Vaccinex, Inc.is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D).
  • Pepinemab is being evaluated in a Phase 1/2a study in Alzheimers Disease, and in a Phase 1b/2 study in recurrent or metastatic head and neck cancer.

Pathway Deep in the Brain Makes It Resilient after Injury

Retrieved on: 
Wednesday, July 6, 2022
Cell, The Pew Charitable Trusts, Mouse, Iran National Science Foundation, Department, University of California, San Francisco, Brain, National Institute of Neurological Disorders and Stroke, Astrocyte, Thalamus, Research, National Institute, Attention, DP2, National Science Foundation, Nutrient, Multimedia, University of Amsterdam, Disease, Seizure, Department of Defense Serum Repository, Mortality, F31, R01, UCSF, Innovation, SAN, Risk, National Cancer Institute, University, Technology, National Institute of Mental Health, Doctor of Philosophy, Neuron, Mental health, DP1, Science Translational Medicine, Gladstone Institutes, Animal, Human, National, Time, Lists of diseases, P30, Injury, MD, UCLA, Mobile phone, Medical imaging, Aroma compound, Trapping, Pharmaceutical industry, Stroke, William Ewart Gladstone

SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- For days, and even years, after someone suffers a stroke or traumatic brain injury, they have an increased risk of developing epilepsy. Now, researchers at Gladstone Institutes discovered that star-shaped cells called astrocytes in the thalamus play a key role in making mice with brain injuries susceptible to seizures.

Key Points: 
  • The team also analyzed human post-mortem brain tissue and showed that the same cells identified in mice might be altered in the thalamus of people affected by brain injury and stroke.
  • The findings, published in the journal Science Translational Medicine, suggest that targeting a protein in these cells could prevent the long-term damage that follows brain injury.
  • At the time of a stroke or traumatic brain injury, many cells at the site of the injury die almost immediately.
  • Previous studies from the team have shown, in rodent models, that activation of astrocytes in the thalamus is a common consequence of brain injury.

New Analysis Finds UPLIZNA® (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Friday, June 24, 2022
Health, Pharmaceutical, Loss of Sensation, Science, Patient, NMOSD, EC, Union, Aquaporin 4, B cell, All European Academies, Royal commission, European Academy of Neurology, Quality of life, Attack, NMO, CD19, Optic nerve, Astrocyte, Pain scale, Spinal cord, Woman, Autoimmunity, Safety, Risk, Instagram, Congress, Twitter, Forward-looking statement, LinkedIn, Experiment, Brain, Poster, Severe cognitive impairment, European Commission, Central nervous system, Neuromyelitis optica spectrum disorder, Autoantibody, Inflammation, Nasdaq, Cell, EMEA, Courage, Adult, Head, Paralysis, U.S. Securities and Exchange Commission, Spectrum disorder, EAN, Physician, Pharmaceutical industry, Medical device, Vaccine, Wood drying, EU, Facebook

These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.

Key Points: 
  • These data are being presented during the 8th Congress of the European Academy of Neurology (EAN), June 25-28 in Vienna.
  • Fewer NMOSD-related hospitalisations were reported among those receiving UPLIZNA compared to those treated with placebo (mean, EU: 1.0 vs 2.0; non-EU: 1.0 vs 1.33).
  • NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes.
  • Baranello RJ, Avasarala, JR. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances.